Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
Condition(s):Prostatic Neoplasms; Genital Neoplasms, Male; Genital Diseases, Male; Prostatic DiseasesLast Updated:March 1, 2018Terminated
Hide Studies Not Open or Pending
Condition(s):Prostatic Neoplasms; Genital Neoplasms, Male; Genital Diseases, Male; Prostatic DiseasesLast Updated:March 1, 2018Terminated
Condition(s):Prostatic NeoplasmLast Updated:March 22, 2023Terminated
Condition(s):Prostate CancerLast Updated:March 6, 2023Recruiting
Condition(s):Metastatic Prostate CancerLast Updated:November 16, 2020Completed
Condition(s):Castration-Resistant Prostatic Cancer; Androgen-Independent Prostatic Cancer; Androgen-Insensitive Prostatic Cancer; Androgen-Resistant Prostatic Cancer; Hormone Refractory Prostatic CancerLast Updated:November 13, 2023Active, not recruiting
Condition(s):NeoplasmsLast Updated:March 27, 2024Active, not recruiting
Condition(s):Prostate CancerLast Updated:June 5, 2019Completed
Condition(s):Metastatic Castration-resistant Prostate CancerLast Updated:February 9, 2024Recruiting
Condition(s):Prostate CancerLast Updated:October 23, 2017Completed
Condition(s):Prostate CancerLast Updated:April 17, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.